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Abstract
A recent genome-wide association study (GWAS) suggested that polymorphisms in or around the genes HCP5, HLA-C and
ZNRD1 confer restriction against HIV-1 viral replication or disease progression. Here, we also find that these alleles are
associated with different aspects of HIV disease, albeit mainly in European Americans. Additionally, we offer that because
the GWAS cohort was a subset of HIV-positive individuals, selected based in part on having a low viral load, the observed
associations for viral load are magnified compared with those we detect in a large well-characterized prospective natural
history cohort of HIV-1-infected persons. We also find that because of linkage disequilibrium (LD) patterns, the dominant
viral load- and disease-influencing associations for the ZNRD1 or HLA-C and HCP5 alleles are apparent mainly when these
alleles are present in HLA-A10-o rHLA-B*57-containing haplotypes, respectively. ZNRD1 alleles lacking HLA-A10 did not
confer disease protection whereas ZNRD1-A10 haplotypes did. When examined in isolation, the HCP5-G allele associates with
a slow disease course and lower viral loads. However, in multivariate models, after partitioning out the protective effects of
B*57, the HCP5-G allele associates with disease-acceleration and enhanced viral replication; these associations for HCP5-G are
otherwise obscured because of the very strong LD between this allele and a subset of protective B*57 alleles. Furthermore,
HCP5 and HLA-C alleles stratify B*57-containing genotypes into those that associate with either striking disease retardation
or progressive disease, providing one explanation for the long-standing conundrum of why some HLA-B*57-carrying
individuals are long-term non-progressors, whereas others exhibit progressive disease. Collectively, these data generally
underscore the strong dependence of genotype-phenotype relationships upon cohort design, phenotype selection, LD
patterns and populations studied. They specifically demonstrate that the influence of ZNRD1 alleles on disease progression
rates are attributable to HLA-A10, help clarify the relationship between the HCP5, HLA-C and HLA-B*57 alleles, and reaffirm a
critical role of HLA-B*57 alleles in HIV disease. Furthermore, as the protective B*57-containing genotypes convey striking
salutary effects independent of their strong impact on viral control, it is conceivable that T cell-based therapeutic vaccine
strategies aimed at reducing viral loads may be inadequate for limiting AIDS progression, raising the potential need for
complementary strategies that target viral load-independent determinants of pathogenesis.
Citation: Catano G, Kulkarni H, He W, Marconi VC, Agan BK, et al. (2008) HIV-1 Disease-Influencing Effects Associated with ZNRD1, HCP5 and HLA-C Alleles Are
Attributable Mainly to Either HLA-A10 or HLA-B*57 Alleles. PLoS ONE 3(11): e3636. doi:10.1371/journal.pone.0003636
Editor: Esper Georges Kallas, Federal University of Sao Paulo, Brazil
Received August 25, 2008; Accepted October 1, 2008; Published November 4, 2008
Copyright:  2008 Catano et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Veterans Administration Center on AIDS and HIV Infection of the South Texas Veterans Health Care System, and by a
MERIT award (R37046326) and other awards (AI043279 and MH069270) from the NIH (to S.K.A.). S.K.A. is a recipient of the Elizabeth Glaser Scientist Award and the
Burroughs Wellcome Clinical Scientist Award in Translational Research. Support for the WHMC cohort was provided by the Infectious Disease Clinical Research
Program (IDCRP) of the Uniformed Services University of the Health Sciences (USUHS), of which the Tri-Service AIDS Clinical Consortium (TACC) is a component.
The IDCRP is a Department of Defense tri-service program executed through USUHS and the Henry M. Jackson Foundation for the Advancement of Military
Medicine (HJF), in collaboration with HHS/NIH/NIAID/DCR through Interagency Agreement HU0001-05-2-0011. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mdolan@hjf.org (MJD); ahujas@uthscsa.edu (SKA)
. These authors contributed equally to this work.
Introduction
An important goal of HIV-1 vaccine research is to identify
vaccine-induced immune responses that will predict protection
from HIV infection or disease. However, this is proving to be an
immensely complex task because it is difficult to predict which
immunological response(s) in candidate vaccine-challenged ani-
mals or in vitro studies will convey a protective effect in humans
[1,2,3]. This is exemplified by the results of the recent STEP trial,
which showed that a HIV-1 vaccine that conferred protection in
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3636non-human primates not only failed to confer protection in
humans, but may have paradoxically increased risk of transmission
[3,4,5,6]. This vaccine failure provides greater urgency for
determining the precise repertoire of host genetic factors that
influence three parameters: risk of HIV acquisition, extent of
initial HIV-1 replication (as reflected by the steady-state viral
load), and rate of disease progression. This is because these three
parameters also may have utility as endpoints for evaluation of
vaccine efficacy [7,8,9,10].
In this quest to identify the correlates of protection that might have
relevance for vaccine development, the immunological features
linked to alleles of class I Human Leukocyte Antigen (HLA) genes,
which reside in the Major Histocompatibility Complex (MHC) locus,
may be especially informative [11]. This is because genetic
association studies have provided incontrovertible evidence demon-
strating that HLA alleles are critical determinants of HIV-AIDS
pathogenesis [11,12,13,14,15,16,17,18]. For example, HLA-B*57 is
among the most intensivelystudied alleles inthe HIV-AIDS fieldas it
is among the most protective HLAclassIalleles.Inmultiplecohortsof
HIV-positive individuals possession of a B*57 allele is associated with
a slower rate of disease progression and strong virologic control
[11,12,14,15,17,19,20,21,22]. Thus, it is conceivable that adminis-
tration of a therapeutic (HIV disease-retarding) vaccine that elicits
immunologic features similar to those associated with disease
protective HLA class I alleles might have benefit in terms of reducing
population-level viral load, and consequently, as modeling studies
suggest, the pace of the epidemic [1,2,23,24,25,26].
The importance of HLA alleles in control of HIV replication is
further illustrated by the results of a recent genome wide
association study (GWAS) because nearly 50% of the top 50
single nucleotide polymorphisms (SNPs) that associated with
virologic control were in or around the MHC locus at 6p21.3
[27]. The selection criteria of subjects for the GWAS were based
on a therapy-naı ¨ve HIV
+ individual of European descent
achieving a steady-state viral load or having a stable low viral
load (,1,000 RNA copies/ml), without knowledge of the date of
seroconversion [27]. 486 subjects met this criteria from the 30,000
HIV-positive subjects screened retrospectively [27]. The two SNPs
that had the strongest association with virologic control were both
near HLA-B*57: the first was a SNP in an endogenous retroviral
element designated as HLA complex P5 (HCP5), and the second
SNP was in the 59-region of the HLA-C gene [27]. Also implicated
as major determinants of AIDS progression rates were seven SNPs
in and around the genes encoding ring finger protein 39 (RNF39)
and zinc ribbon domain–containing 1 (ZNRD1), which are in close
proximity to the HLA-A locus [27].
Thus, the main inferences of this GWAS were: (i) HLA-C and
ZNRD1 are key independent host determinants associated with
control of HIV replication and disease progression, respectively,
and (ii) HCP5 may contribute positively to the well-described
protective effects attributed to HLA-B*57, as this allele was found
to be in nearly 100% linkage disequilibrium (LD) with the HLA-
B*5701 allele. This GWAS clearly represents an advance for the
HIV-AIDS field, and the results served as a fulcrum to probe
further the importance of the MHC locus in HIV-AIDS
pathogenesis. To understand further the role of HLA alleles in
AIDS pathogenesis we reflected on the following three points.
First, the SNPs in HCP5 and HLA-C accounted for ,9.6% and
,6.5% of the variability in steady-state viral load, respectively
[27]. Despite these high percentages and the prior observation that
viral load is highly predictive of clinical outcome [28,29], these
polymorphisms were not among those identified when disease
progression was used as a phenotypic endpoint [27]. For example,
the association between the HLA-C allele and viral load exceeded
the threshold for statistical significance imposed by a GWAS, but
the association of this allele for disease progression was not
statistically significant [27]. Additionally, the SNP in HCP5 was
not identified in the GWAS screen for disease progression, despite
being in nearly 100% LD with the HLA-B*5701 allele, which in
multiple cohorts has been associated with better virologic control,
as well as a slower rate of disease progression [15,17,19,21,27,30].
These observations (strong association for the SNPs in HLA-C and
HCP5 for viral load, but not for disease progression) suggested that
perhaps epidemiological considerations, such as the combined
analyses of subjects who achieve steady-state viral load and HIV
controllers [31], might have inadvertently led to an enrichment of
subjects with genotypes that might confer enhanced restriction of
viral replication, and under-representation of individuals who have
progressive disease during the early stages of infection. Hence,
alleles that might associate with disease acceleration may not be
fully represented in the study sample examined, and conceivably,
this may obscure genotype-phenotype associations that might be
detected within the context of a natural history cohort of HIV-1-
infected subjects.
Second, there is a high degree of LD between SNPs in the
MHC locus and HLA alleles [32,33]. It thus remained conceivable
that the effects attributed to the three SNPs identified in the
GWAS (HCP5, HLA-C and ZNRD1) were due, in part, to their LD
with HLA class I alleles that affect viral load and/or disease course.
Third, we and others have shown that the host genetic
determinants of HIV-AIDS pathogenesis may be population-
specific [34,35,36]. Since the GWAS was restricted to subjects of
European descent, we considered whether the reported SNPs also
influenced other populations.
For these three reasons, we sought to achieve greater clarity
regarding the phenotypic effects associated with the SNPs in the
three genes identified in the GWAS on steady-state viral load and
disease progression rates. We conducted these analyses in a large,
well-characterized U.S.-based natural history cohort of HIV-1-
positive individuals, whose clinical characteristics have been
described before [34,36,37,38,39]. We evaluated the genotype-
phenotype associations attributable to the SNPs in HCP5, HLA-C
and ZNRD1 before and after accounting for patterns of LD with
HLA alleles that were in close proximity to these SNPs in the entire
cohort, and separately in subjects of European and African descent.
Results
LD patterns of SNPs with HLA alleles
We genotyped HIV
+ and HIV
2 subjects in the Wilford Hall
Medical Center (WHMC) cohort for the SNP in HCP5 (rs2395029;
designated as HCP5-T.G), the 59-region of the HLA-C gene
(rs9264942, designated as HLA-C59-T.C), as well as for the seven
SNPs in or near the ZNRD1 and RNF39 genes (Figure 1A). We had
previously genotyped subjects from the WHMC HIV
+ cohort for
HLA class I alleles [38]. We evaluated the pair-wise patterns of LD
between the SNPs, as well as between the SNPs and HLA class I
alleles in HIV
+ individuals. The seven SNPs near the ZNRD1 locus
that were found to be associated with inter-subject differences in
HIV disease course in the GWAS were all found to be in nearly
100% LD with each other (Figure 1B and Figure 1C, bottom).
Predictably, consistent with these very high LD patterns, the
genotype-phenotype associations reported below did not differ
significantly when we analyzed each of the seven SNPs near ZNRD1
separately (data not shown). Hence, the results reported here are for
a single SNP near ZNRD1 (rs9261174; third ZNRD1-RNF39 SNP
shown in Figure 1B and Figure 1C, bottom), and this polymorphism
is designated here as the ZNRD1-T.C SNP.
HLA, HCP5 and ZNRD1 in HIV
PLoS ONE | www.plosone.org 2 November 2008 | Volume 3 | Issue 11 | e3636Figure 1. Polymorphisms analyzed in this study and their LD patterns in HIV
+ subjects from the WHMC cohort. (A) Genomic location of
the polymorphisms studied on chromosome 6p21. Green ticks/boxes represent the HCP5, RNF39 and ZNRD1 genes and red ticks denote HLA loci. The
relative location of the polymorphisms studied is shown by vertical arrows (along with their respective NCBI rs identifiers). The horizontal arrows
under the genes point to the 59R39 orientation of the gene. The predicted size of the two extended haplotypes containing HLA-A10 (,86kb) and
B*57 (,157kb) are also shown. (B) Linkage disequilibrium (LD) analysis of the studied alleles. D’ value estimates are denoted by the intensity of the
blue color shown on the scale on the top. (C) Estimated frequencies of the haplotypes based on possession of the HLA-B*57, HCP5 and HLA-C59
polymorphisms (top), and separately for HLA-A10 and ZNRD1 (bottom) polymorphisms in HIV
+ individuals from the WHMC cohort. Top panel shows
the haplotype frequencies for HLA-B*57, HCP5 and HLA-C59 alleles (red and purple colored bars are for EAs and AAs, respectively) while the lower
panel is for haplotypes derived based on HLA-A10 and ZNRD1 polymorphisms (red and purple colored bars are for EAs and AAs, respectively). Bars
represent the haplotype frequency while the numbers to the right of each bar represents the number of haplotypes found in the WHMC subjects.
Numbers in parentheses, total number of haplotypes. As discussed in the text, because of the nearly 100% LD between ZNRD1 and RNF39 SNPs,
rs9261129 was used to represent the ZNRD1 SNP in statistical analyses (SNP number 3 in panels B and panel C, bottom).
doi:10.1371/journal.pone.0003636.g001
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SNP (Figure 1A) prompted us to investigate whether the latter
SNP was in LD with specific HLA-A alleles. We considered the
results of de Bakker et al [32] who found a high LD between HLA-
A*2601 and the SNP designated as rs2301751. The latter SNP is
244 bp from rs2301753, which is one of the seven ZNRD1-RFN39
SNPs that we genotyped. Furthermore, rs2301753 is reported to
be in very high LD (D’=1.0) with rs2301751 by the HapMap
project in Utah residents of European descent. Accordingly, we
found a very strong LD between the ZNRD1 SNP with not only
HLA-A*26, but also with A*25, which along with HLA-A*34 and
HLA-A*66 make up the serogroup HLA-A10 [40] (Figure 1B and
Figure 1C, bottom). Among the WHMC HIV
+ subjects, the
HLA-A10 group was composed mainly of HLA-A*25 and HLA-
A*26 alleles (89% of the alleles that categorize to the HLA-A10
serogroup) in European Americans (EAs), whereas HLA-A*34 and
HLA-A*66 alleles (78% of the alleles that categorize to the HLA-
A10 serogroup) were more common in African Americans (AA;
Table 1 in Materials S1). This difference in the distribution of
alleles that belong to the HLA-A10 serogroup across the two major
ethnic groups in the WHMC HIV
+ cohort was statistically
significant (x
2=72.7; P=1.1610
215).
Consistent with the results of the GWAS [27], a nearly 100%
LD was noted between the HCP5 SNP and B*5701 (Figure 1B
and Table 2 in Materials S1). Moreover, there was a high
degree of LD between the HCP5-G, HLA-C59-C and HLA-B*57
alleles, and the HLA-C59-C/HLA-B*57/HCP5-G-containing hap-
lotype was found almost exclusively in European Americans
(Figure 1B and Figure 1C, top). No significant differences were
found in the frequency of these SNPs among HIV-infected and -
uninfected individuals (Table 3 in Materials S1).
Because of the observed LD patterns, in the analyses described
below, we examined whether the influence on disease course of the
SNPs in ZNRD1 or HCP5 and HLA-C were independent of HLA-
A10 and HLA-B*57, respectively.
Effects of ZNRD1 SNP on HIV disease
In the entire cohort of WHMC HIV
+ subjects, heterozygosity
but not homozygosity for the ZNRD1-C allele was associated with
disease-retardation (Figure 2A, left panel). We stratified the
cohort based on whether subjects were EAs or African Americans
(AAs), and the stratified analysis revealed that the disease-retarding
effects associated with the ZNRD1-C allele was restricted mainly to
EAs (Figure 2A, middle and right panel). These results are
consistent with the observations by Fellay et al [27] who found that
the ZNRD1-C allele is associated with a slower disease course in
subjects of European descent. However, we also found that this
allele does not influence HIV disease course in HIV-positive
African Americans in the WHMC cohort.
We next determined whether the disease retarding effects
associated with the ZNRD1-C allele were due to those associated
with alleles categorized to the HLA-A10 serogroup for three
reasons. First, the ZNRD1-C allele was in high LD with HLA-A10
(Figure 1B and Figure 1C, bottom) and of the 60 HIV-positive
EAs who possessed an allele corresponding to the serogroup A10,
52 subjects also possessed at least one ZNRD1-C allele. Second, the
ZNRD1-C allele was associated with a reduced rate of disease
progression to AIDS only in HIV
+ EAs (Figure 2A). Similarly,
only HIV
+ EAs who possessed alleles corresponding to the HLA-
A10 serogroup had a significantly slower rate of progression to
AIDS compared to those who lacked alleles corresponding to the
A10 serogroup (Figure 2B). An association between HLA-A10 and
disease course was not detected in HIV
+ AA (data not shown).
Notably, the strength of the disease-retarding effects (relative
hazards, RH) associated with HLA-A10 were similar before
(RH=0.62) and after (RH=0.44) adjustment for explanatory
covariates that in previous studies we had found influenced disease
progression in this cohort ([39]; Figure 2B). The strength of the
protective effects associated with HLA-A10 were also consistent
when the analysis was restricted to subjects who had not received
highly active antiretroviral therapy (HAART) (RH=0.52; 95%
confidence interval (CI)=0.028–0.93; P=0.028 for comparison of
those possessing and lacking HLA-A10; Figure S1). Third, we
surmised that if both HLA-A10 and ZNRD1-C each had
independent effects on disease, then the protective effects of the
ZNRD1-C allele that are not because of its LD with HLA-A10
should be evident in those 85 individuals who possessed at least
one ZNRD1-C allele but lacked alleles corresponding to A10
serogroup. For these reasons, we stratified HIV
+ EAs into six
genotypic groups based on their ZNRD1-C allele and/or HLA-A10
status (Figure 2C). Those lacking both ZNRD1-C and HLA-A10
served as the reference category in the statistical analyses
(Figure 2C, group 1).
Subjects possessing one ZNRD1-C allele but lacking HLA-A10
(Figure 2C, group 2) had a disease course that was indistinguish-
able from those who lacked both ZNRD1-C and HLA-A10 alleles
(group 1). This suggested that in itself the ZNRD1-C allele was not
associated with disease-retarding effects in the HIV
+ EAs we
examined (Figure 2D, compare survival curves for genotypic
groups 1 and 2). By contrast, subjects who possessed both a
ZNRD1-C and a HLA-10 allele (group 5) had a slower rate of
disease progression (Figure 2D, compare survival curves for
group 5 versus group 1 (P=0.004) or group 2 (P=0.057)).
Additionally, although the number of subjects was small, those
who were HLA-A10+ but lacked the ZNRD1-C allele (group 4) also
had a slower disease course that was comparable to those in group
5 who were A10+ but possessed a ZNRD1-C allele (Figure 2D).
These data indicated that the disease-retarding effect associated
with the ZNRD1-C allele is evident only when it resides on a
haplotype that also contains HLA-A10. The failure to detect an
effect of the ZNRD1-C allele on disease course that is independent
of HLA-A10 did not appear to be due to insufficient sample size
because there were more HIV-positive EAs who possessed one
ZNRD1-C allele but lacked HLA-A10 (n=83) than those who had
one allele each of ZNRD1-C and HLA-A10 (n=50; Figure 2D).
Furthermore, similar to what was observed for HLA-A10, the
associations for the six genotypic groups defined by HLA-A10 and
ZNRD1-C genotypes remained consistent when the analysis was
restricted to subjects who had not received HAART (data not
shown).
The survival curves associated with homozygosity for ZNRD1-C
suggested that it might be associated with a rapid rate of disease
progression (Figure 2A, middle; RH=4.26; 95% CI=1.36–13.3;
P=0.013). Although there were few subjects who were homozy-
gous for the ZNRD1-C allele with (group 6) or without HLA-A10
(group 3), it was interesting to note that subjects assigned to either
of these two groups had a progressive disease course (Figure 2D).
The small sample sizes preclude firm inferences but the direction
of the effects associated with ZNRD1-A10 genotypic groups 3and 6
suggest that homozygosity for the ZNRD1-C allele might associate
with disease acceleration even in those instances when these
genotypes contain HLA-A10 alleles.
The results shown in Figure 2D were derived from the
genotype of HLA-A10 and ZNRD1-C alleles. To confirm that the
aforementioned inferences derived from the associations of these
compound HLA-A10/ZNRD1 genotypes are valid, we determined
the disease-influencing effects of the individual A10-ZNRD1
haplotypes shown in Figure 1C in the EA component of the
HLA, HCP5 and ZNRD1 in HIV
PLoS ONE | www.plosone.org 4 November 2008 | Volume 3 | Issue 11 | e3636Figure 2. Disease-influencing effects associated with HLA-A10/ZNRD1-containing genotypes. (A) Plots are Kaplan-Meier curves for time to
AIDS (1987 criteria). Disease-influencing effects of the ZNRD1 SNP in all subjects (left column), and in the European American (middle column) and
African American (right column) components of the WHMC cohort. (B) Kaplan-Meier plots depicting the influence on rate of disease progression of
alleles categorized into the HLA-A10 serogroup. The relative hazards (RH) and 95% confidence intervals (CI) were computed before (values above the
complete horizontal line) and after (values below the complete horizontal line) adjustment for ethnic background, cohort membership across
different therapy eras, CCL3L1-CCR5 genetic risk group status and whether date of seroconversion was known. (C) Six genotypic groups (enumerated,
color-coded) were derived by accounting for HLA-A10 status and the ZNRD1 genotype. Number of subjects in each genotypic group are shown within
the color-coded boxes. (D) Kaplan-Meier plot for the disease-influencing effects of the six genotypic groups (Gp) shown in panel C. RH, CI, and
significance values are depicted to the right and were obtained by Cox proportional hazards modeling. n, number of subjects. Group 1 (Lacking HLA-
HLA, HCP5 and ZNRD1 in HIV
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haplotype level (Figure S2) provide further confirmation that the
effects associated with the ZNRD1-C allele occur only when this
allele is present on the same haplotype on which alleles that
categorize to the HLA-A10 serogroup exists. First, haplotype 2
bears the ZNRD1-C allele but lacks HLA-A10 (Figure 1C,
bottom), and in the heterozygous state this haplotype is not
associated with disease retardation and in the homozygous state it
is associated with disease acceleration (Figure S2B; reference
category are those lacking haplotype 2). Second, heterozygosity for
the haplotype that bears both ZNRD1-C and HLA-A10 (haplotype
3; Figure 1C, bottom) is associated with a slower rate of disease
progression (Figure S2C; reference category are those lacking
haplotype 3). Third, those who are heterozygous for the haplotype
that bears HLA-A10 but not ZNRD1-C (haplotype 5; Figure 1C,
bottom) have a slower disease course than those lacking this
haplotype (Figure S2D).
Taken together, the analyses conducted thus far at the
compound genotype (Figure 2D) and haplotype/haplotype pair
levels (Figure S2) together demonstrate that in the cohort we
examined, the ZNRD1-C allele does not have independent disease
protective effects, and instead, the associations observed for the
ZNRD1-C allele occur because of its LD with HLA-A10, i.e, they
are attributable to the disease-modifying effects of alleles
corresponding to the HLA-A10 serogroup. Further underscoring
the importance of HLA-A10 in AIDS pathogenesis in EAs is the
observation that the HLA-A10-bearing haplotype that lacks
ZNRD1-C, albeit low in frequency, is associated with disease
retardation (Figure 2D, group 4, and Figure S2D). This suggests
further that HLA-A10 influences AIDS pathogenesis independent
of ZNRD1-C.
To further confirm that the ZNRD1-C allele does not influence
disease independent of its association with HLA-A10,w e
conducted univariate and multivariate analyses. In univariate
analyses, both heterozygosity for ZNRD1-C (RH=0.69; P=0.030)
and HLA-A10 (RH=0.46; P=0.005) associated with a reduced
rate of disease progression (Table 1 under the column designated
as ‘Time to AIDS’). However, in multivariate models, HLA-A10
(RH=0.51; P=0.028) but not the ZNRD1-C (RH=0.85;
P=0.409) allele was associated with a reduced rate of disease
progression (Table 1).
The aforementioned genotype-phenotype association analyses
were conducted using AIDS (1987 criteria) as a phenotypic
endpoint. Therefore, it was plausible that although the ZNRD1-C
allele did not have a direct impact on disease progression rates to
AIDS it influenced surrogate markers of disease (e.g., viral load,
baseline CD4
+ T cell count). However, we found that subjects who
had one ZNRD1-C allele but lacked an HLA-A10 allele (group 2)
were similar to those who lacked both ZNRD1-C and HLA-A10
alleles (group 1) with respect to their baseline, cumulative and
nadir CD4
+ T cell counts, as well as steady-state viral load and
delayed type hypersensitivity skin test reactions (a measure of cell
mediated immunity [39]) (Figure 2E). Subjects in group 5
(heterozygosity for the HLA-A10/ZNRD1-C-containing haplotype)
were also similar to those in group 1 with respect to most of these
laboratory and immunologic characteristics, except those in group
5 had lower cumulative CD4
+ T cell counts, a parameter that
reflects the amount of CD4
+ T cell loss over disease course and is a
parameter that is highly correlated with development of AIDS
([39]; Figure 2E). These findings conveyed two points: first, in the
cohort examined, the ZNRD1-C allele was unlikely to have an
impact on disease independent of its LD with HLA-A10; and
second, the influence of the HLA-A10/ZNRD1-C-containing
haplotype on disease course occurs independent of an impact on
the viral load, and that the influence of this haplotype is restricted
mainly to the rate and extent of CD4
+ T cell loss (assessed by
cumulative CD4
+ T cell count; Figure 2E), and by extension, on
AIDS progression rates (Figure 2D).
To clarify further the relationship between the ZNRD1-C allele
and steady-state viral load, we determined the influence of
ZNRD1-C and HLA-A10 on viral load using univariate and
multivariate linear regression analyses. In these analyses, the alleles
were considered as independent variables and the steady-state viral
load was considered as the dependent variable. These analyses
revealed that the impact of the ZNRD1 allele on viral load was
minimal and HLA-A10 had no influence on viral load (as reflected
Table 1. HIV disease-influencing effects associated with HLA-A10 status and ZNRD1 heterozygosity in European Americans.
Model Covariates Time to AIDS Steady-state viral load
RH 95% CI P Coeff 95% CI PR
2
1 ZNRD1 Heterozygosity 0.69 0.49 – 0.96 0.030 20.14 20.29 to 0.02 0.077 0.0036
2 HLA-A10 0.46 0.27 – 0.79 0.005 20.07 20.28 to 0.15 0.534 0.0007
3 ZNRD1 Heterozygosity 0.85 0.59 – 1.24 0.409 20.15 20.33 to 0.03 0.092
HLA-A10 0.51 0.28 – 0.93 0.028 0.04 20.21 to 0.29 0.746 0.0055
Results are from multivariate Cox proportional hazards regression (for the outcome of time to AIDS) and linear regression models (for the outcome of log10 steady-state
viral load).
RH, relative hazards; CI, confidence interval, Coeff, regression coefficient obtained from linear regression model
R
2, the explained variability in steady-state viral loads was assessed using the R
2 estimated by analysis of variance (ANOVA). Analysis of ZNRD1-C homozygosity was not
included in this analysis because of the small sample number.
doi:10.1371/journal.pone.0003636.t001
A10 and ZNRD1-C) is used as a reference. (E) Association between HLA-A10/ZNRD1-containing genotypes with virologic-immunologic markers of HIV
disease. Group 1 (lacking HLA-A10 and ZNRD1-C) is used as a reference and comparisons are made to HLA-A10/ZNRD1 genotypic groups 2 and 5. {M-
W P refers to significance values obtained by Mann-Whitney test. bCD4, nCD4, and cCD4 represent baseline and nadir CD4
+ T cell counts (cells/mm
3,
mean (6SE)), and cumulative CD4
+ T cell count (x10
5 cell-days/mm
3, mean (6SE)), respectively; the latter parameter provides a measure of the
change in CD4
+ T cell count during disease course as described previously [39]. VL, steady-state viral load (log10 HIV mRNA copies/ml, mean (6SE)).
DTH, delayed type hypersensitivity skin test reactivity (an in vivo parameter of cell-mediated immunity) was examined as described previously [39]
and data reflect the mean (6SE) number of positive skin tests out of the four applied.
doi:10.1371/journal.pone.0003636.g002
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2 values and non-significant P values in Table 1
under column designated as ‘Steady-state viral load’).
Effects of HLA-C and HCP5 on disease progression
Because of (i) their proximity to HLA-B*57, (ii) the previously
reported dominant protective role of B*57 alleles in virologic
control and disease progression, and (iii) the high degree of LD
between the HLA-C59-C, HLA-B*57 and HCP5-G alleles (Figure 1B
and Figure 1C, top), we determined whether the effects
attributable to the SNPs in HLA-C and HCP5 were in part due
to these LD patterns and their presence within HLA-B*57-
containing genotypes. To this end, we used strategies that were
complementary to those we used to clarify the relationship
between ZNRD1 and HLA-A10 alleles. We first evaluated the
associations and distributions separately for the HLA-B*57, HLA-
C59 and HCP5 alleles (Figure 3), and then because of their LD
patterns, we determined the associations for B*57-containing
genotypes that contained or lacked HLA-C59 and HCP5 alleles
(Figure 4). We took this analytical approach of first analyzing the
genotype-disease-influencing phenotypes at the level of the
haplotype and then haplotype pairs (genotypes), as ultimately the
phenotypic effect is conveyed by the genotype.
In univariate analyses, possession of a B*57 allele (Figure 3A,
and Table 2, model 1), and heterozygosity and homozygosity for
the HLA-C59-C allele (Figure 3B and Table 2, model 2) were
each associated with significant protective effects on the rate of
disease progression to AIDS. The impact of the HLA-C59-C allele
on disease progression was greater in EAs than AAs (Figure 3B).
In univariate analyses, the HCP5-G allele was associated with
protective effects on disease progression, but this trend did not
achieve statistical significance and was mostly restricted to EAs
(Figure 3C and Table 2, model 3).
Consistent with the results of the univariate analyses, with
increasing AIDS-free status, there was a statistically significant
step-wise increase in the proportion of subjects possessing a HLA-
B*57 allele, including the B*5701 allele (Figure 3D). A similar
statistically significant trend for a shift in distribution with
increasing AIDS-free status was also observed for the HLA-C59-
C allele (Figure 3D). Thus, compared to subjects who developed
AIDS within 2 years, HIV
+ subjects who were AIDS-free for more
than 10 years were 12.7, 5.6 and 2.1 times more likely to possess a
HLA-B*57, HLA-B*5701 and the HLA-C59-C allele, respectively
(Table 3). Increasing AIDS-free status was also associated with a
trend for enrichment of the HCP5-G allele although this
association was not significant (Figure 3D and Table 3). It was
noteworthy that the degree of enrichment of subjects with the
HCP5-G allele with increasing AIDS-free status was similar to that
observed for the HLA-B*5701 subtype (Figure 3D). This
observation is consistent with the LD between HLA-B*5701
subtype and the HCP5-G allele (D’=0.91 for EAs and 0.73 for
AAs, Figure 1B).
When placed in a multivariate model with HLA-B*57,
heterozygosity and homozygosity for the HLA-C59-C indepen-
dently associated with disease-retardation (Table 2, compare
models 2 and 4). However, the statistical significance of the
protective effects associated with HLA-C59-C in multivariate
models were slightly lower than those observed in univariate
models (Table 2, compare models 2 and 4). This was most
prominent for homozygosity for HLA-C59-C as the hazard ratios
for the rate of progression to AIDS were 0.66 (P=0.025) and 0.72
(P=0.067) in univariate and multivariate analyses, respectively
(compare models 2 and 4, Table 2). These results indicated that
possibly because of its LD with HLA-B*57, the strength of the
disease-retarding effects associated with HLA-C59-C may in part be
due to the effects conferred by the HLA-B*57 allele.
In univariate analysis, the hazard ratio for the rate of disease
progression to AIDS associated with the HCP5-G allele was ,1
(RH=0.67, 95% CI=0.39–1.14, P=0.135), suggesting that this
allele might convey weak disease-retarding effects (Table 2, model
3). However, when examined in the context of a multivariate
model with B*57, the hazard ratio for the HCP5 allele was .1
(RH=2.06; 95% CI=0.98–4.33, P=0.056; Table 2, model 5).
Conversely, in the univariate analyses, the hazard ratio for rate of
disease progression associated with the B*57 allele was 0.38
(P=0.0002, Table 2, model 1), whereas when examined in the
context of a multivariate model with HCP5-G, the hazard ratio was
lower (RH=0.25) and the strength of the association increased
(P=0.0001 Table 2, model 5). When HLA-C59-C heterozygosity
and homozygosity were also added to the multivariate model
(Table 2, model 6), the strength of the observed detrimental and
beneficial effects associated with the HCP5-G and B*57 alleles,
respectively, on disease progression became even further accen-
tuated (Table 2, compare models 5 and 6).
We inferred that the opposing direction of the disease-
influencing effects associated with the HCP5-G allele in the
univariate (RH,1, protective effects) and multivariate (RH .1,
detrimental effects) analyses, and the accentuation of the protective
effects of the B*57 in the multivariate models, convey the
following: when examined at the haplotype level, those haplotypes
which contain both B*57 and HCP5-G alleles are associated with a
faster rate of disease progression compared to those B*57-
containing haplotypes that bear the HCP5-T allele. Consequently,
in multivariate models when the overall beneficial effects of B*57
are partitioned out or accounted for, the HCP5-G allele, which is in
nearly 100% LD with a subset of HLA-B*57 alleles, associates with
disease-acceleration. Conversely, in multivariate models when the
effects of B*57/HCP5-G haplotypes are partitioned out, the overall
beneficial effects associated with B*57 are accentuated. Concor-
dant results (and inferences) were obtained when we studied the
association of the HLA-C59–HLA-B–HCP5 haplotypes shown in
Figure 1C with rates of disease progression (Figure S3).
Influence of HLA-C and HCP5 on viral load
We next examined whether the direction and the relative
strength of the effects observed for the HLA-B*57, HCP5 and HLA-
C59 alleles on rates of disease progression are similar to those
observed when the steady-state viral load is used as a phenotypic
endpoint. The hierarchal order of the extent to which the B*57,
HLA-C and HCP5 alleles explained the variability in the steady-
state viral load in the WHMC HIV
+ cohort (R
2 estimates as
percentages are in parenthesis; Table 2) was: B*57 (3.2%; model
1).HLA-C (0.72%; model 2).HCP5 (0.38%; model 3). These
findings indicated that at least within the context of a natural
history cohort, the SNPs in HLA-C and HCP5 explained only one-
third to one-tenth of the variability in steady-state viral load than
the B*57 allele, and several fold less than the reported estimates in
the GWAS [27].
To further evaluate the influence of these alleles on viral load,
univariate and multivariate linear regression analyses were
conducted in which these alleles were considered as independent
variables and the steady-state viral load was considered as the
dependent variable. Univariate analysis revealed that (i) a HLA-
B*57 allele, (ii) one (heterozygosity) or two (homozygosity) copies of
the HLA-C59-C allele, and (iii) a HCP5-G allele each associated with
a lower steady-state viral load (as reflected by the negative values of
the regression coefficients; Table 1, models 1 to 3). However, the
viral load-mitigating effects observed for possession of the HCP5-G
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PLoS ONE | www.plosone.org 7 November 2008 | Volume 3 | Issue 11 | e3636Figure 3. Disease-influencing effects associated with the HLA-B*57, HLA-C59 and HCP5 alleles in HIV-infected subjects from the WHMC
cohort. (A–C) Plots are Kaplan-Meier curves for time to AIDS (1987 criteria). Disease-influencing effects in all subjects (left column), and in the European
American (middle column) and African American (right column) componentsof the WHMCcohort that are associated with(A) HLA-B*57 alleles, (B) theSNP
in HLA-C59 and (C) the SNP in HCP5. RH, relative hazards; CI, confidence interval; P, significance value obtained by Cox proportional hazards modeling; n,
number of subjects. (D) Distribution of the indicated alleles in the WHMC HIV
+ cohort stratified according to time to AIDS or duration of AIDS-free status.
These are indicated as time to AIDS in ,2, 2 to ,5, and $5 years, and no development of AIDS during the first 10 years or after 10 or more years of follow-
up.Forexample,withineachpaneltheleft-mostbarcorrespondstosubjectswhodevelopedAIDSwithin2yearswhiletheright-mostbarindicatessubjects
who did not develop AIDS after 10 or more years of follow-up. At the bottom of each panel is shown significance value (obtained using chi-square test for
linear trend) for a linear trend in the proportion of subjects possessing the indicated allele.
doi:10.1371/journal.pone.0003636.g003
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model 3) was not evident when this allele was examined in a
multivariate context with B*57 alone (Coeff=0.46; P=0.005,
Table 1, model 5), or with the B*57 allele and HLA-C59 genotypes
together (Coeff=0.56; P=0.001, Table 1, model 6). Thus, the
opposing direction of the viral load-influencing effects of the HCP5-
G allele observed in the univariate (negative value for the regression
coefficients in Table 1, model 3; Coeff=20.25) and multivariate
(positive value for the regression coefficients in Table 1, models 5
(Coeff=0.46) and 6 (Coeff=0.56)) analyses closely mirrored the
opposing direction of the disease-influencing effects of the HCP5-G
allele observed in univariate and multivariate analyses. Thus, once
the protective effects associated with HLA-B*57 or HLA-C59-C are
partitioned out, the HCP5-G allele associated with not only a faster
rate of disease progression (RH=2.19; 95% CI=1.07–4.46;
P=0.032), but also a higher viral load (Coeff=0.56; 95%
CI=0.23–0.88; P=0.001; Table 1, model 6).
Analyses of the final multivariate regression model also revealed
that the HLA-B*57, HLA-C59 and HCP5 alleles together explained
4.66% of the variability in the steady-state viral load in the
WHMC HIV
+ cohort (R
2 estimate for model 6 in Table 2).
Additionally, the final model indicates that HLA-B*57 alleles might
confer a greater protective effect on early viral replication than
HLA-C59 alleles (Coefficient values in model 6 in Table 2 for
B*57 was 20.82, whereas it was HLA-C592 0.08 and 20.26 for
heterozygosity and homozygosity for the HLA-C59-C allele).
Table 2. Analysis of the disease-modulating effects of HLA-B*57, the HLA-C59 and HCP5 alleles/genotypes in HIV
+ subjects from the
WHMC cohort.
Model Covariates Time to AIDS Steady-state viral load
RH 95% CI P Coeff 95% CI PR
2
1 HLA-B*57 0.38 0.23–0.63 0.0002 20.53 20.71 to 20.35 7.1610
29 0.0324
2 HLA-C59
Heterozygosity 0.81 0.65–0.99 0.041 20.07 20.18 to 0.03 0.172 0.0072
Homozygosity 0.66 0.46–0.95 0.025 20.26 20.42 to 20.09 0.003
3 HCP5 0.67 0.39–1.14 0.135 20.25 20.48 to 20.02 0.030 0.0038
4 HLA-B*57 0.39 0.24–0.65 0.0003 20.51 20.69 to 20.33 2.9610
28 0.0368
HLA-C59
Heterozygosity 0.81 0.66–1.00 0.051 20.06 20.16 to 0.04 0.270
Homozygosity 0.72 0.50–1.02 0.067 20.21 20.38 to 20.05 0.012
5 HLA-B*57 0.25 0.13–0.51 0.0001 20.79 21.05 to 20.54 1.3610
29 0.0392
HCP5 2.06 0.98–4.33 0.056 0.46 0.14 to 0.78 0.005
6 HLA-B*57 0.26 0.13–0.51 8.5610
25 -0.82 21.07 to 20.56 3.7610
210 0.0466
HLA-C59
Heterozygosity 0.81 0.66–0.99 0.043 20.08 20.18 to 0.02 0.124
Homozygosity 0.69 0.48–0.99 0.044 20.26 20.43 to 20.09 0.002
HCP5 2.19 1.07–4.46 0.032 0.56 0.23 to 0.88 0.001
Results are from univariate and multivariate Cox proportional hazards regression (for the outcome of time to AIDS (1987 criteria)) and linear regression models (for the
outcome of log10 steady-state viral load) in all subjects from the WHMC cohort.
RH, relative hazards; CI, confidence interval, Coeff, regression coefficient obtained from linear regression model.
R
2, the explained variability in steady-state viral loads was measured using the R
2 estimated by analysis of variance (ANOVA).
doi:10.1371/journal.pone.0003636.t002
Figure 4. Disease-influencing effects associated with HLA-B*57/HCP5/HLA-C-containing genotypes. (A) Six genotypic groups
(enumerated, color-coded) were derived by accounting first for the presence or absence of HLA-B*57 alleles and the wild-type (T/T), heterozygous
(T/C) or homozygous (C/C) state for the SNP in HLA-C. This group of subjects was stratified further based on presence or absence of the HCP5-G allele.
Number of subjects in each genotypic group is shown within the color-coded boxes. ‘‘+’’ and ‘‘-’’ denotes ‘‘presence’’ and ‘‘absence’’, respectively. (B)
The disease-influencing effects associated with the six genotypic groups shown in panel A. (C) Kaplan-Meier plots depicting the influence of the HCP5
SNP on disease progression in subjects in genotypic group 2 stratified according to presence (group 2A) or absence (group 2B) of the HCP5-G allele. P
values in panels B and C are by the logrank test. (D) HLA-B*57/HCP5/HLA-C genotypes that associate with nonprogressive disease (B*57-NPD, i.e.,
groups 1, 2B and 3 depicted in panels A–C) or progressive disease (B*57-PD; group 2A depicted in panel A and C) compared with genotypes that lack
HLA-B*57. RH, relative hazards; CI, confidence interval; P, significance value obtained by Cox proportional hazards modeling; n, number of subjects.
The RH was computed before (values above complete horizontal line) and after (below) adjustment for ethnic background, cohort membership
across different therapy eras, CCL3L1-CCR5 genetic risk group status and whether date of seroconversion was known. All plots are Kaplan-Meier
curves for time to AIDS development (1987 criteria). (E) Association of the genotypes shown in panel D with virologic and immunologic markers of
HIV disease. {M-W P refers to significance values obtained by Mann-Whitney test for comparison between HLA-B*57-NPD genotype and the
remaining cohort subjects. bCD4, nCD4, cCD4, VL and DTH are as described in Figure 2E. (F) The distribution of HLA-B*57-NPD or HLA-B*57-PD
genotypes was examined according to time to AIDS or duration of AIDS-free status (left panel) as well as according to steady-state viral load (right
panel). Data are from all subjects in the cohort. Time to AIDS or duration of AIDS-free status is shown on the bottom of the left panel and indicates
time to AIDS in ,2, 2 to ,5, and $5 years, and no development of AIDS during the first 10 years or after 10 or more years of follow-up. Steady-state
viral load shown on the right was categorized as ,10,000, 10,000 to ,20,000, 20,000 to ,55,000 and $55,000 copies/ml. P value at the top of left
panel is significance value for a linear trend obtained using chi-square test for linear trend.
doi:10.1371/journal.pone.0003636.g004
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The aforementioned findings indicated that the ‘protective’
phenotype attributable to B*57 (e.g. Figure 2A) is a composite,
i.e., an overall phenotype that is evident before accounting for the
independent phenotypic effects of the SNPs in HLA-C and HCP5-
G. Based on the LD patterns between the HLA-B*57, HCP5-G and
HLA-C59-C alleles (Figure 1B and Figure 1C, top) and
associations described above for each of these alleles, we surmised
that a more accurate assessment of the phenotypic effects
attributable to B*57 alleles might be attained by evaluation of
the genotype-phenotype relationships for B*57-containing geno-
types that are defined based on whether or not they also contained
the HCP5-G and/or HLA-C59-C alleles. Conversely, such an
approach we surmised would also provide insights into the extent
to which the protective effects attributed to the HLA-C59-C allele is
due to its presence in B*57-containing genotypes. To investigate
this, we categorized subjects into six genotypic groups which
permitted an analysis of the phenotypic effects associated with
HCP5 and HLA-C alleles in genotypes that contained or lacked a
B*57 allele (Figure 4A).
These six genotypic groups together explained ,3.1% of
variability in steady-state viral load (as analyzed by R
2) and
conferred differential rates of disease progression (Figure 4B).
Examination of the survival curves for these six genotypic groups
revealed the following genotype-phenotype relationships.
Subjects lacking a B*57 allele were assigned to genotypic groups
4t o6( Figure 4A). Predictably, as group 4 lacked a B*57 allele as
well as the protective HLA-C59 allele, subjects within this group
displayed the fastest rate of disease progression among the six
genotypic groups (Figure 4B). It was noteworthy that in those
subjects who lacked B*57, but were heterozygous (group 5) or
homozygous (group 6) for the HLA-C59-C allele had comparable
rates of disease progression (Figure 4B). This contrasted with the
observation that when LD patterns with the B*57 allele had not
been accounted for, homozygosity for the HLA-C59-C allele was
associated with a greater protective effect against disease
progression than heterozygosity for this allele (Figure 3B). The
latter finding indicated that the maximal protective effects of HLA-
C59-C allele on HIV disease course might be evident when this
allele is present in HLA-B*57-containing genotypes, and the data
presented below affirm this possibility.
Subjects with a B*57 allele were assigned to genotypic groups 1
to 3, but despite containing a B*57 allele, these genotypic groups
were associated with contrasting disease-influencing effects
(Figure 4B). Compared to subjects assigned to genotypic groups
1 or 3, those in group 2 had a faster rate of disease progression
(Figure 4B). The distribution of the HCP5-G allele in group 2
revealed that individuals assigned to this group could be stratified
into two broad categories, with subgroups 2A and 2B possessing or
lacking a HCP5-G allele, respectively (Figure 4A). Remarkably,
none of the 10 subjects categorized to group 2B progressed to
AIDS (Figure 4C), and they all had a genotype that contained a
HLA-B*57 and a HLA-C59-C allele but lacked a HCP5-G allele
(Figure 4A). By contrast, the HCP5-G-carrying subjects catego-
Table 3. Likelihood of possessing specific alleles in subjects with different rates of HIV disease progression.
Allele N Group
{ OR (95% CI), P
Unadjusted Adjusted
{
HLA-B*57 90 1 1.00 1.00
145 2 3.18 (0.37–27.66), 0.295 3.10 (0.36–27.04), 0.306
184 3 5.11 (0.64–40.59), 0.123 4.76 (0.60–37.89), 0.140
585 4 8.87 (1.21–64.93), 0.032 7.62 (1.02–56.69), 0.047
168 5 12.71 (1.68–96.16), 0.014 10.80 (1.42–82.05), 0.021
HLA-B*5701 90 1 1.00 1.00
145 2 2.52 (0.28–22.95), 0.411 2.41 (0.26–22.03), 0.437
184 3 4.05 (0.50–32.85), 0.191 4.03 (0.49–32.92), 0.194
585 4 4.14 (0.55–30.89), 0.166 4.42 (0.58–33.81), 0.153
168 5 5.63 (0.71–44.73), 0.102 5.59 (0.70–44.87), 0.105
HCP5-G 98 1 1.00 1.00
157 2 3.19 (0.37–27.72), 0.293 3.05 (0.35–26.68), 0.314
198 3 4.62 (0.58–36.99), 0.149 4.63 (0.57–37.35), 0.150
612 4 4.48 (0.60–33.33), 0.143 4.84 (0.63–36.94), 0.128
184 5 4.99 (0.62–39.96), 0.130 5.10 (0.63–41.25), 0.127
HLA-C59-C 98 1 1.00 1.00
157 2 1.32 (0.80–2.19), 0.281 1.28 (0.76–2.14), 0.351
198 3 1.30 (0.80–2.12), 0.285 1.27 (0.77–2.09), 0.341
612 4 1.36 (0.89–2.09), 0.159 1.47 (0.93–2.32), 0.096
184 5 2.16 (1.31–3.55), 0.003 2.16 (1.29–3.60), 0.003
Results of multinomial logistic regression analyses and data are derived from all subjects in the HIV+ WHMC cohort.
{Group 1 (progression to AIDS in less than two years) is the reference group, groups 1–5 are as defined in Figure 3D.
{Adjusted for seroconversion, race, and the moderate and high CCL3L1-CCR5 genetic risk groups (GRG), which in previous studies were identified as independent
determinants of AIDS development [39].
N, number of subjects.
doi:10.1371/journal.pone.0003636.t003
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differential disease outcomes associated with groups 2A and 2B
indicated that genotypes which contained a HCP5-G allele
associated with disease acceleration despite containing two
separate ‘protective’ alleles namely a HLA-B*57 and HLA-C59-C
allele (group 2A). Thus, the genotype-phenotype relationship for
group 2A (which contains both HLA-B*57 and HCP5G alleles) may
explain why when examined in a multivariate model, possession of
the HCP5-G allele was associated with both disease acceleration
and higher viral loads (Table 2, model 6).
The phenotype of subjects in group 3 was also very instructive
(Figure 4B). These subjects were homozygous for HLA-C59-C and
possessed B*57 and had among the slowest rates of disease
progression (Figure 4B). This occurred despite the fact that most
subjects in group 3 also possessed the HCP5-G allele. Thus, among
those who possessed B*57, the disease-accelerating effects
associated with the HCP5-G allele was evident in those with one
(group 2A) but not two (group 3) HLA-C59-C alleles (Figure 4B).
These observations underscore our previous thesis [34,41] that
analyses conducted at the allele level obscure complex genotype-
phenotype relationships that occur when the phenotypic effects of
both haplotypes are accounted for.
These survival curves also underscore two other points: First, a
HLA-B*57-containing genotype does not require the presence of a
‘protective’ HLA-C allele to convey a protective effect on disease
progression. This is reflected by the observation that subjects in
group 1 who have a B*57 allele and are homozygous for the HLA-
C59-T allele have a slow disease course. Second, the maximal
‘protective’ effects associated with possession of a HLA-C59-C allele
occurs only when it is present in a HLA-B*57-containing genotype.
This is reflected by the observation that subjects assigned to B*57-
containing genotypic groups 2B or 3 have a much slower disease
course than those categorized to B*57-lacking genotypic groups 5
and 6 (Figure 4, B and C, compare survival curves for groups 2B
and 3 vs those for groups 5 and 6).
B*57-containing genotypes and progressive disease
There is clinical, virologic and immunologic data indicating a
conundrum: some subjects despite possessing a ‘protective’ B*57
have a progressive disease course [20,22,42]. We surmised that the
genotype-phenotype relationships shown in Figure 4B and
Figure 4C might address this paradox as they showed that subjects
with HLA-B*57-containing genotypes classify into two categories.
The first group are those subjects with genetic features present
in genotypic groups 1, 2B or 3 as these genotypic groups are
associated with a non-progressive disease (NPD) course (Figure 4,
B and C), and collectively these genotypes are designated here as
B*57-NPD genotypes in Figure 4D. In the overall cohort, B*57-
NPD genotypes conferred a nearly 83% slower rate of disease
progression compared to genotypes that lack a B*57 allele
(RH=0.17, 95% CI=0.07–0.41, P=7.2610
25; Figure 4D, left
panel). These associations detected at the level of the entire cohort
(Figure 4D, left panel) remained consistent after adjustment for
covariates known to influence disease progression in this cohort,
including ethnicity [39,43].
The second group are those subjects categorized to group 2A
and, compared to those with B*57-NPD genotypes, the clinical
course of subjects in this group is characterized by a progressive
disease (PD; designated as B*57-PD genotype in Figure 4D).
Remarkably, the disease course of those with a B*57-PD genotype
is similar to those who lack a B*57 allele (Figure 4D). Consistent
genotype-phenotype relationships were also evident when similar
analyses were conducted separately in HIV
+ EAs and AAs before
and after adjusting for covariates (Figure 4D; middle and right
panels) or when the analyses were restricted to subjects who did
not receive HAART (Figure S4). In these HAART-free subjects,
those assigned to the B*57-NPD genotypic group had a nearly
80% lower risk of progressing to AIDS than those who lacked a
B*57 allele (RH=0.21; 95% CI=0.08–0.57; P=0.002).
Based on the aforementioned findings we surmised that the
comparison of the immunologic (CD4
+ T cell profiles and DTH
skin test reactivity) and virologic (viral load) profiles would reveal a
step-wise worsening in subjects categorized to B*57-NPD, B*57-
PD and those lacking a B*57 allele. In general agreement with this,
as a general rule, there was a step-wise decrease in the baseline,
cumulative and nadir CD4
+ T cell counts as well as DTH
responses in subjects assigned to B*57-NPD, B*57-PD and those
lacking B*57 (Figure 4E). Conversely, in subjects categorized to
B*57-NPD, B*57-PD and those lacking B*57 there was a step-wise
increase in the steady-state viral load (Figure 4E). The only
exception to this general rule was that the baseline CD4
+ T cell
counts in subjects assigned to B*57-NPD and B*57-PD were
similar, but they were higher than the cell counts found in those
who lacked a B*57 allele (Figure 4E).
To validate that B*57-containing NPD and PD genotypes
convey contrasting phenotypic effects during HIV disease course
we used a complementary approach and determined the
distributions of these genotypes as a function of increasing AIDS-
free status and steady-state viral loads with the intent of testing two
premises. First, although increasing AIDS-free status is associated
with a stepwise enrichment of subjects with a B*57-containing
genotype (Figure 3D), the greatest enrichment should be for those
with B*57-NPD genotypes. Second, the B*57-NPD and not B*57-
PD genotypes should be enriched for subjects with a low steady-
state viral load. The data shown in Figure 4F (left panel) provides
evidence in support for the first premise. Nearly 12 percent of those
HIV-positive individuals who were AIDS-free after 10 years of
follow-up possessed a B*57-containing genotype, and strikingly
,90% of these subjects were those with a B*57-NPD genotype
(Figure 4F, left panel). The data shown in Figure 4F (right panel)
provides evidence in support of the second premise as among
subjects with a steady-state viral load lower than 10,000 copies/ml,
there was an overrepresentation of those with B*57-NPD
genotypes. It was noteworthy that the proportion of subjects with
a B*57-PD genotype was similar in those who had a steady-state
viral load of ,10,000 and $55,000 copies/ml (Figure 4F). Thus,
these distribution patterns (Figure 4F) provide additional validity
for the categorization of B*57-containing genotypes into B*57-
NPD and B*57-PD genotypes as a means to improve the accuracy
of identifying those B*57-carrying subjects who may have a slower
disease course or control of viral replication during the early phases
of infection.
Viral load-independent effects of B*57-NPD genotypes
Based on the well-established, strong relationship between
steady-state viral load and AIDS development [28,29], one
interpretation of the aforementioned findings might be that the
B*57-NPD genotypes convey disease-retardation by simply
influencing the extent of early viral replication. However, in a
recent study, we found that although the steady-state viral load is a
strong predictor of AIDS risk, it accounted for only ,12% of the
variability in AIDS progression rates [39]. The findings by
Rodriguez et al also suggest that the contribution of viral load to
the explained variability in the rate of decline in CD4
+ T cell
counts might not be very large [44,45]. These data indicated that
parameters that are independent of viral load are also critical
determinants of AIDS pathogenesis. We therefore used nested
multivariate Cox proportional hazards models (Table 4) to assess
HLA, HCP5 and ZNRD1 in HIV
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independent of the viral load.
Before accounting for any of the covariates, those HIV-positive
persons categorized to B*57-NPD had an ,83% lower risk of
progressing to AIDS compared to individuals who lacked a HLA-
B*57 allele (RH=0.17; 95% CI=0.07–0.41; Table 4, model 1).
We next adjusted–individually and in unison–for the disease-
influencing effects of several explanatory variables. These analyses
revealed that even after adjustment for the disease-influencing
effects of these covariates, the B*57-NPD genotypes remained
strong independent predictors of a slow rate of disease progression
(Table 4, models 2 to 10). By contrast, the rates of disease
progression among those categorized to B*57-PD and those
lacking a B*57 allele were not statistically different (Table 4,
model 1), and this association remained after inclusion of the other
covariates in the model (Table 4, models 2 to 10).
Discussion
The salient genetic-epidemiologic findings of this study conducted
in a natural history cohort of HIV-1 subjects are as follows. First,
because of their LD patterns, the associations for ZNRD1 alleles were
evident only when these alleles were also present with alleles that
categorize to the HLA-A10 serogroup. Second, heterozygosity and
homozygosity for the HLA-C59 allele were associated with disease
retardation, but because of LD between HLA-C and B*57 alleles, the
maximal beneficial effects associated with HLA-C-bearing genotypes
were evident when they were present in HLA-B*57-containing
genotypes. Third, because the HCP5-G allele is in nearly 100% LD
with the B*5701 allele, the genotype-phenotype relationships
observed for genotypes that contain B*57 and HCP5-G alleles
reflected those of B*5701-containing genotypes. We find that those
HCP5-G-carrrying individuals who have one copy of HLA-C59-C (i.e.,
heterozygous for HLA-C59-C) had a progressive disease course
whereas most of those who bear two copies of the HLA-C59-C allele
(i.e., homozygous for HLA-C59-C) have a nonprogressive disease
course. Fourth, after partitioning out the protective effects of B*57,
the HCP5-G allele was associated with disease-acceleration and
enhanced viral replication, and these associations for HCP5-G were
otherwise masked because of its LD with the protective B*57 alleles.
Fifth, ZNRD1 alleles influenced disease course without impacting on
the viral load. Sixth, the influence of the HLA-C on the steady-state
viral load was much lower than that of HLA-B*57 alleles, and the
extent of variability in steady-state viral load that can be explained by
HLA-C alleles independent of HLA-B*57 was significantly lower than
that reported previously [27]. Seventh, because of the aforemen-
tioned LD and genotype-phenotype patterns, we find that B*57-
containing genotypes could be stratified into two categories, one of
which associated with striking disease retardation, the other with a
diseasecoursethatissimilartothatobservedinindividualswholacka
B*57 allele. Finally, we found that B*57-containing genotypes that
associate with a slower disease course influenced progression rates by
impacting both the viral load as well as parameters that are
independent of the viral load. Below, we discuss the seven major
implications of these findings within the context of how they apply to
AIDS pathogenesis, vaccine development, and genotype-phenotype
association studies.
First, our results provide a basis to clarify the role of ZNRD1 in
HIV pathogenesis. Using several different analytical approaches we
find that in the European American component of the HIV
+ cohort
we studied, associations of the alleles in or around ZNRD1 or RNF39
with disease progression are not attributable to an independent effect
of these alleles on HIV disease course, but rather to their strong LD
with HLA-A10 alleles. In the cohort studied, there was a higher
proportion of subjects who had ZNRD1-containing haplotypes that
lacked HLA-A10 than individuals with ZNRD1-C/A10-containing
haplotypes. Despite this, ZNRD1-C/A10-lacking haplotypes were not
associated with a slower rate of disease progression whereas the
ZNRD1-C/A10-containing haplotypes were. Additionally, HLA-A10-
containing genotypes that lacked ZNRD1 alleles were also associated
with a slower disease course. Collectively, these findings suggest that
HLA-A10 may be an important determinant of the rate of HIV
disease progression in European Americans. Previous association
studies also suggest that serogroup HLA-A10 may convey a protective
effect [46]. Additionally, HLA-A*25 (a subtype of A10)i sk n o w nt o
present gag epitopes [47,48,49], and HLA-A*26 (a subtype of A10)
restricted gag responses have been also reported [50]. These prior
reports in conjunction with our genetic epidemiologic findings invoke
the possibility that HLA-A10 carriers elicit protective immune
responses against key HIV-1-derived peptides, and consideration of
this possibility might have value for understanding the host factors
that influence AIDS pathogenesis and for vaccine development.
Table 4. Viral load-independent disease-influencing effects of HLA-B*57-containing genotypes.
Model # Covariates N B*57-PD RH (95% CI), P B*57-NPD RH (95% CI), P
1 None 1,126 0.90 (0.49–1.64), 0.734 0.17 (0.07–0.41), ,0.001
2 Baseline CD4 (C) 974 1.33 (0.73–2.44), 0.347 0.22 (0.09–0.54), 0.001
3 Nadir CD4 (N) 974 0.95 (0.52–1.73), 0.867 0.24 (0.10–0.59), 0.002
4 Steady-state VL (V) 977 1.34 (0.73–2.45), 0.342 0.21 (0.07–0.67), 0.008
5 DTH (D) 973 0.66 (0.36–1.22), 0.185 0.20 (0.08–0.48), ,0.001
6 Moderate-High GRG (G) 1,102 0.81 (0.44–1.48), 0.492 0.18 (0.07–0.43), ,0.001
7 C, N 974 1.17 (0.64–2.14), 0.612 0.27 (0.11–0.66), 0.004
8 C, N, V 829 1.19 (0.65–2.18), 0.582 0.25 (0.08–0.78), 0.017
9 C, N, V, D 828 0.92 (0.50–1.73), 0.806 0.24 (0.08–0.76), 0.015
10 C, N, V, D, G 815 0.85 (0.45–1.62), 0.629 0.25 (0.08–0.80), 0.019
Results are from nested multivariate Cox proportional hazards models for the outcome of time to AIDS (1987 criteria) for subjects assigned to B
*57-PD and B
*57-NPD
before (none, model 1) and after adjustment for covariates individually (models 2 to 6) or in unison (models 7 to 10). Data is presented as relative hazard (RH) with 95%
CI and P values. The reference group for all the comparisons is those who lack a B
*57 allele (relative hazard=1). N, number of subjects. B
*57-PD represents subjects who
possess B
*57-containing genotypes that associate with progressive disease whereas B
*57-NPD represents subjects who possess B
*57-containing genotypes that
associate with non-progressive disease (as shown in Figure 4D).
doi:10.1371/journal.pone.0003636.t004
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ZNRD1 in AIDS pathogenesis as it was among the more than 250
candidate genes identified by a large-scale siRNA screen used to
identify host factors required by HIV-1 [51].
Second, our results may provide a basis to clarify the disease- or
viral load-influencing effects of the SNPs in HCP5 and HLA-C.( i )I n
multivariate models, after accounting for the protective effects of
HLA-B*57 alleles, we find that the HCP5-G appears to have
detrimental effects on both viral load and disease progression. Thus,
we surmise that when examined in isolation the true phenotypic
effects associated with the HCP5-G allele might be obscured because
of its strong LD with protective B*57 alleles. We propose that the
protective associations detected previously for the HCP5-G allele [27]
are perhaps due to a specific set of B*57-containing genotypes, i.e.,
those that are also homozygous for the HLA-C59-C allele (Figure 4,
group 3). (ii) Based on the LD between B*57 and HLA-C59-C alleles
and the significant beneficial influence of HLA-B*57-containing
genotypes on viral restriction and disease course observed here and in
many prior studies [11,12,14,17,19,20,21,22], we suggest that the
dominant protective effects attributable to HLA-C59-C alleles may be
because of their presence in specific B*57-containing genotypes. (iii)
We suggest that the differences in the extent to which the HLA-C59
and HCP5 alleles explained the variability in the steady-state viral
load detected in a natural history cohort versus that observed in the
GWAS might relate to epidemiological considerations. The com-
bined analysis of subjects who achieved a steady-state viral load and
thosewhohad virologic characteristics similar tothose ofspontaneous
HIV controllers [31,52,53] might be one reason why such a strong
association for viral load was detected for HLA-C59 and HCP5 alleles,
yet these alleles were not among those detected when using disease
progression as a phenotypic endpoint [27]. Consistent with this
possibility, the preliminary results of a separate GWAS in HIV
controllers also revealed an association between HLA-C59 and HCP5
alleles and restriction of viral replication [54]. We are mindful that
other epidemiologic considerations might also contribute to differing
genotype-phenotype associations. This could include the criteria used
to define disease progression, which was rate of CD4 decline or time
to initiation of HAART in the GWAS [27] versus a clinical endpoint
used herein. Thus, it is conceivable that the varying (i) characteristics
(e.g., ethnicity, risk behavior) of the subjects, (ii) selection criteria used
for entry into the study as well as (iii) phenotypic endpoints used may
collectively account for some of the differences in the results of the
genotype-phenotype association studies.
Third, the LD patterns detected herein are not completely
unanticipated because the MHC locus is known to have small
recombination rates and a high degree of LD, hence, increasing the
number of extended haplotypic blocks in this genomic area [32].
The nature of these extended haplotypes differ in their genetic
composition and the prevalence of these extended haplotypes also
vary significantly according to continent-of-origin [32]. Notably,
several extended HLA haplotypes that have relevance to HIV-AIDS
have been identified [55,56]. LD with protective HLA alleles might
provide a basis for why a large proportion of the SNPs identified in
the GWAS were in the MHC locus, including additional HCP5 and
HLA-C SNPs [27]. Similar considerations of LD might also have
applicability to the inferences of GWAS for other diseases in which
HLA-B*57 and other HLA alleles play pathogenic roles. For
example, a recent GWAS implicated the HCP5-G allele as a
determinant of psoriasis [57].
Fourth, we provide a genetic basis for the long-standing but highly
underappreciated conundrum of why some B*57-carrying individ-
uals have a progressive disease course whereas others exhibit a
strikingly slow clinical course [19,20,22,42]. The prevailing viewpoint
is that possession of a B*57 allele confers strong protection against
early viral replication and disease progression. However, the studies
especially of Migueles et al [19] and Navis et al [22] suggest that a
substantial proportion of HIV
+ subjects who possess a B*57 allele,
including those possessing B*5701 can have a progressive disease
course. A very striking example of this conundrum was reported
recently by Bailey et al who studied a HIV-1 transmission pair [42]:
w h i l eb o t ht r a n s m i s s i o np a i r sw e r eHLA-B*57 positive, the
transmitter progressed to AIDS, whereas the recipient was an elite
controller. The contrasting clinical phenotypes of nonprogressive vs
progressive disease course associated with carriage of a HLA-B*57
allele has been attributed to differences in cytotoxic T lymphocyte
(CTL) escape mutations and CTL activity against epitopes in Gag as
well as to differential viral replication capacities [20,22]. Here, we
show that specific HLA-C59/HLA-B*57/HCP5 containing genotypes
may represent multiplex ‘genetic signatures’ that have differential
effects on HIV disease course. These genetic findings have broad
biologic and public health significance as the immunologic features
linked to protective vs non-protective B*57-containing genotypes
may have practical value inachieving a detailed understanding of the
immunologic correlates of virologic control and nonprogressive
disease.
Fifth, our findings place a spotlight on that aspect of pathogenesis
that is influenced by parameters whose effects are independent of
the viral burden. This point is illustrated by two observations (i)
HLA-A10 affects disease course without influencing the viral load,
and (ii) HLA-B*57-containing genotypes that convey a nonprogres-
sive disease course do so partly by restricting viral replication (as
reflected by the viral load) and also by impacting on parametersthat
are independent of the viral load. These observations are
reminiscent of our previous results where we found that CCL3L1-
CCR5 genotypes also influence disease progression, in part, by
impacting on parameters that are independent of the viral load
[37,38]. Although the full nature of these viral load-independent
parameters is as yet unknown, their importance in pathogenesis is
inferred from (i) prior findings showing that the viral load does not
explain the full extent of variability in AIDS progression rates [39]
or rate of CD4 cell decline [44,45], and (ii) findings in non-human
primates who are naturally infected with simian immunodeficiency
virus, as these animals exhibita non-progressive disease despite high
viralloads[58].Hence,considerationofboththeviralloadandviral
load-independent parameters might help mitigate the confounding
that may occur in HIV vaccine and genetic-epidemiologic studies in
which the viral load is used as the primary surrogate marker for
vaccine efficacy or disease outcome, respectively. Additionally,
findings from animal studies [2] and mathematical modeling
[23,24,25,26] support the hope that imperfect, T-cell based
disease-modifying, i.e., therapeutic vaccines, by reducing plasma
viral load at the population level might abate the epidemic.
However, the clinical [44,45], and genotype-phenotype relation-
ships observed herein and previously [39] raise the possibility that
for a therapeutic vaccine to be efficacious in mitigating disease
progression rates, in addition to reducing the viral load, the vaccine
may also need to target pathogenic viral load-independent factors.
Sixth, within the context of a natural history cohort of HIV-
positive individuals we find that there is a gradual enrichment of
protective HLA-B*57 genotypes in subjects who remain AIDS free
for a prolonged duration. This gradual shift emphasizes that the
relative contribution of a genetic factor that confers the phenotype
of nonprogressive disease within the context of a natural history
cohort may not be identical to the contribution of the same genetic
factor in subjects who are selected for analyses based on specific
clinical characteristics such as those with nonprogessive disease
(e.g., long-term nonprogressors), or virologic characteristics such as
untreated subjects who maintain very low viral loads during some
HLA, HCP5 and ZNRD1 in HIV
PLoS ONE | www.plosone.org 14 November 2008 | Volume 3 | Issue 11 | e3636period of the disease course (e.g., elite or viremic controllers) [31].
For example, Migueles et al [19] found that the HLA-B*5701 allele
is dramatically overrepresented in long-term nonprogressors.
When studied within the context of a natural HIV history cohort,
we find that 6.6% of EAs possess a B*5701 allele and of these 64%
have progressive disease. Thus, the very high frequency of the
HLA-B*5701 allele among those selected because of nonprogres-
sive disease or a low viral load may represent an estimate specific
to this selected subset of HIV-positive subjects, because HIV-
positive individuals who have progressive disease are unlikely to be
well represented in such a study group. Hence, association studies
in such selected patients are more likely to identify genetic factors
that are skewed towards having a significant impact on restriction
of viral replication or nonprogressive disease, and may not
necessarily identify the full realm of host factors that influence
pathogenesis in the context of the natural clinical course of HIV
disease, especially because a proportion of AIDS pathogenesis is
independent of the viral load [39,44,45].
Finally, the results of the present study support our previous thesis
that the host determinants of HIV pathogenesis are likely to be highly
population-specific [34,36]. Similar inferences were also reported by
Winkler and colleagues [35]. In this study, we found that the impact
of the A10/ZNRD1, HLA-C and HCP5 alleles on disease course were
evident mainly in subjects of European descent. Some of these race-
specific effects are not related to the differential distribution in the
frequency of these polymorphisms in European and African
Americans. The exact basis for these race/ethnicity-specific effects
on HIV disease is unclear. Given the differing evolutionary histories
of the populations examined, one possibility is that the race/ethnicity-
specific effects observed might relate to the interplay between
polymorphismsin different gene systemsthat played an ancestral role
in the contrasting host-microbe interplay found in subjects of
European and African descent. For example, we found recently that
the disease-accelerating effects of the CCL5 -471A/A genotype in
African Americans is evident only in those who do not bear the
African-specific -46C/C genotype of Duffy Antigen Receptor for
Chemokines (DARC), a genotype which is thought to have arisen due
to the selective pressure of specific malaria-causing species [43].
Regardlessoftheprecisereasonsforthe observedrace-specificeffects,
they add a tier of underappreciated complexity as they point to
population-specific correlates of protection. Consequently, the
development and evaluation of an effective HIV vaccine might need
to factor in not just HIV diversity, but also host genetic diversity.
Methods
Study subjects
HIV-positive subjects were from the Department of Defense
(DoD) HIV Natural History Study (NHS) cohort followed at
Wilford Hall Medical Center (WHMC) and more recently at the
Brooke Army Medical Center (BAMC), San Antonio, TX. The
studied population is the local component of a prospective multisite
observational cohort from the United States Military’s Tri-Service
AIDS Clinical Consortium (TACC) HIV Natural History Study.
Unidentified cast-off blood from subjects participating in training at
Lackland AFB, TX was used for the HIV-negative control
population. The demographic and clinical characteristics of the
HIV-positive WHMC cohort have been described extensively
[34,36,37,38,39,59,60,61]. The voluntary, fully written informed
consent of the subjects studied in this research was obtained as
required by Air Force Regulation 169-9 and additional approval
from the Institutional Review Board (IRB) of the University of
Texas Health Science Center, San Antonio, TX.
Genotyping
Genotyping for HLA-B*57 and HLA-B*5701 subtypes was
undertaken in 1,143 HIV
+ subjects. Polymorphisms in the HCP5
(rs2395029), HLA-C59 (rs9264942) and seven SNPs in and around
ZNRD1-RNF39 genes (Figure 1A) were genotyped in 1,230 HIV
+
subjects and 1,129 HIV-negative subjects. Haplotypes based on
HLA-A10 status and the seven ZNRD1 SNPs as well those based on
HLA-B*57, HCP5 and HLA-C59 alleles were generated using
unphased data. For this purpose, we used the PHASE software.
Detailed materials, methods and description of the study cohort
are available as supporting online material (Materials S1).
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